

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 January 2022 (20.01.2022)



(10) International Publication Number
WO 2022/013405 A1

(51) International Patent Classification:

A61K 39/12 (2006.01) C07K 14/005 (2006.01)
A61P 31/14 (2006.01) C12N 15/86 (2006.01)

(21) International Application Number:

PCT/EP2021/069890

(22) International Filing Date:

15 July 2021 (15.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/052,264 15 July 2020 (15.07.2020) US
63/130,202 23 December 2020 (23.12.2020) US
PCT/IB2021/000293
02 February 2021 (02.02.2021) IB

(71) Applicants: **INSTITUT PASTEUR** [FR/FR]; 25-28, rue du Docteur Roux, 75724 PARIS CEDEX 15 (FR). **THER-AVECTYS** [FR/FR]; Bâtiment Pasteur Biotop 28 rue du Docteur Roux, 75724 PARIS CEDEX 15 (FR).

(72) Inventors: **CHARNEAU, Pierre**; c/o Pasteur-TheraVectys Joint Lab Institut Pasteur, 25-28, rue du Docteur Roux, 75724 PARIS CEDEX 15 (FR). **KU, Min-Wen**; c/o Pasteur-TheraVectys Joint Lab Institut Pasteur, 25-28, rue du Docteur Roux, 75724 PARIS CEDEX 15 (FR). **AUTHIE, Pierre**; c/o Pasteur-TheraVectys Joint Lab Institut Pasteur, 25-28, rue du Docteur Roux, 75724 PARIS CEDEX 15 (FR). **ESCRIOU, Nicolas**; c/o Pasteur-TheraVectys Joint Lab Institut Pasteur, 25-28, rue du Docteur Roux, 75724 PARIS CEDEX 15 (FR). **BOURGNE, Maryline**; c/o Pasteur-TheraVectys Joint Lab Institut Pasteur, 25-28, rue du Docteur Roux, 75724 PARIS CEDEX 15 (FR). **MAJLESSI, Laleh**; c/o Pasteur-TheraVectys Joint Lab Institut Pasteur, 25-28, rue du Docteur Roux, 75724 PARIS CEDEX 15 (FR).

(74) Agent: **ERNEST GUTMANN- YVES PLASSERAUD SAS - DESAIX ANNE, SELLIN CAROLE, DERAMBURE CHRISTIAN, JOLLY CHRISTOPHE, LE QUERÉ HERVÉ, LEJEUNE ANNE, PERNOT PIERRE, PICHAT THIERRY, POUCHAIN DELPHINE, ROBERT MATHIAS**; 66, rue de la Chaussée d'Antin, 75009 PARIS (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: SARS-COV-2 IMMUNOGENIC COMPOSITIONS, VACCINES, AND METHODS

(57) Abstract: A method of inducing a protective immune response against Severe Acute Respiratory Syndrome beta-coronavirus 2 (SARS-CoV-2), comprising administering to the upper respiratory tract of a subject an effective amount of an agent that induces a protective immune response against SARS-CoV-2. A dosage form for administration to the upper respiratory tract of a pseudotyped lentiviral vector particle encoding a Severe Acute Respiratory Syndrome beta-coronavirus 2 (SARS-CoV-2) spike (S) protein or a derivative or fragment thereof.

WO 2022/013405 A1